Background: The use of inhaled corticosteroids (ICS) and long-acting 2 adrenergics (LABA) in fixed combination (ICS/LABA) was recently extended to COPD patients with a baseline FEV 1 50-60% predicted, thus broadening the original guideline indications (GOLD 2006) that limited their use only to stages III and IV. Method: The present study was carried out to assess the clinical profile of this new subset of patients, with a view to providing data for future studies on the impact of this novel extension of ICS/LABA use in COPD. Results: Data from the present observational cross-sectional study suggest that COPD patients with FEV 1 50-60% predicted depict a dichotomic condition: actually, even though resembling milder patients in terms of frequency and severity of their respiratory symptoms, they are much more similar to severer patients in terms of rate of hospital admissions and resource consumption (p50.01). In other words, this subset of patients seems to represent a peculiar condition in the evolutional phase of COPD during which therapeutic treatment should be intensified in order to slow down the disease progression effectively. Nevertheless, independently of the severity, the general therapeutic approach to COPD was found to be greatly inadequate when compared to GOLD guidelines, particularly in terms of appropriateness. Conclusions: These findings should pave the way for future studies aimed to long-term monitoring of main outcomes and to evaluate the overall impact of earlier ICS/LABA use on disease progression and lung function decline in COPD.
Introduction
Chronic obstructive pulmonary disease (COPD) is an airway disease characterized by noncompletely reversible bronchial obstruction [Global Initiative for Chronic Obstructive Lung Disease, 2006 ]. COPD is a major cause of morbidity and mortality worldwide and, in Italy, has a prevalence of approximately 5% in the general population [ISTAT, 2008; European White Book 2003; Viegi et al. 2001 ]. Disease management is complex and involves smoking cessation (which plays a fundamental role in over 60% of cases), symptoms control, lung function improvement, reduction of the exacerbation rate, an improved quality of life and containment of health costs.
In comparison with the duration and natural history of COPD (which spans several decades), many of these outcomes have been and are often still evaluated over too short a time period (1-3 years) to be able to establish their absolute value as markers of efficacy of disease management [Calverly et al. 2007 ].
Moreover, generally speaking, research over the past few years has been largely focused on evaluating the effects and benefits of treatment in the more severe stages of COPD (GOLD stages III and IV), without considering the possibility that current therapeutic options may also be effective for the earlier stages of the disease, and capable of influencing its course.
According to a wide consensus based on international guidelines and scientific evidence, the course of treatment involves a gradual escalation of therapeutic drugs, with specific options indicated as appropriate for the different stages of COPD severity. In particular, use of combinations of inhaled corticosteroids (ICS) and longacting 2 adrenergics (LABA) was envisaged starting from stage III (baseline FEV 1 550% of predicted) or in cases of frequent exacerbation.
However, on the strength of findings from major international studies, very recently the indication for use of fixed combinations of ICS and LABA (ICS/LABA) has been extended also to subjects with a baseline FEV 1 50-60% of predicted -this represents an expansion of the indication to cases of lower clinical severity, at least in functional terms [Calverley et al. 2007 ]. The aim of the present study was to describe the clinical profile of this new subgroup with respect to the total population of COPD patients for which this treatment option was already planned and to verify the potential significance and impact of this recent extension of the indication of therapeutic appropriateness.
Materials and methods
The patient sample was automatically extracted from the institutional Health Services database and comprised more than 50 000 subjects affected by respiratory diseases. Extraction procedures are based on full Boolean selective criteria [Dal Negro et al. 1984] . The database has been certified according to ISO 9001-2000 norms since 1999.
Patients chosen for the cross-sectional sample had to be subjects aged 418 years, male or female, coming from any geographical zone within Italy, affected by COPD with baseline FEV 1 80% of predicted, reporting for a first visit as outpatient in the period 1 January to 31 December 2007. Of these subjects, only information contained in the file related to their first visit could be utilized; thus, in order to better to reflect the management reality of the local territory and ensure the absolute absence of any behavioural and/or treatment bias stemming from the relationship with our specialist centre. The subject group thus selected was then subdivided into different subgroups based on the baseline value of 'FEV 1 % of predicted' recorded in the database. The personnel responsible for the selection procedures and then for creating the databank were not members of the staff of the Division of Pneumology, but were professionals of an agency to whom we outsourced this specific task of the study protocol.
The information to extract from the '1st visit' file of all subjects responding to the selection criteria were as follows: sex age smoking habit baseline lung function (FEV 1 % predicted and FEV 1 /FVC%) clinical symptoms reported number of hospital admissions, of specialist and GP visits, of exacerbations and of work days lost in the last 12 months treatment approach followed (drug classes only).
On the basis of their FEV 1 value, subjects were subdivided into five groups: 470 80%; 460 70%; 450 60%; 430 50% and 530%. For all parameters, data were expressed in absolute values and/or percentage, and mean AE s.d. Statistical comparisons were performed using Anova-Duncan test; p50.05 was considered as significant.
Results
From the selection process, a overall sample of 571 subjects with COPD was identified. Of these, 330 (57.8%) were subjects with FEV 1 580% predicted, on whom all subsequent analyses were focused: subjects were then subdivided into different subgroups according to the decreasing value of their FEV 1 % predicted as indicated in the methods. The number of patients in each subgroup is reported in Table 1 , while their characteristics; that is, age, sex, and smoking habit (in both males and females) are presented in Table 2 .
The subgroups were homogeneous in terms of age, sex, and prevalence of active smokers (ANOVA ¼ n.s.): a non-negligible proportion of patients were still active smokers, ranging from 19% in the most severe to 30-36% in moderate patients. Also the number of patients in each subgroup was fairly similar, except for the very severe group which was the least represented. As can be seen from Tables 1 and 2, males were predominant in all subgroups, and also smoking habit was associated predominantly with males (who comprised more than 70% of smokers in all subgroups).
In general, COPD was confirmed as a disease of clear male predominance in this patient sample, as is the smoking habit, which was demonstrated to be associated more than 70% with males. Of note, a consistent portion (20%) of patients fell within the subgroup of FEV 1 50-60% predicted; thus one in five subjects with FEV 1 580% belong to this particular subgroup of COPD patients. Also these subjects resulted homogeneous in terms of age, sex and smoking habit.
From a clinical point of view, the symptoms most frequently reported (alone or in various combination) by subjects with FEV 1 580% predicted were: dyspnoea (87.7%), cough (51.8%), chronic sputum (36.0%) and wheezing (23.3%). Overall, these four symptoms represented 94.5% of all symptoms reported. Of note, among patients who reported dyspnoea, this was exercise-induced dyspnoea in 78.8% of cases. Cough was reported as productive in 69.5% of cases. Wheezing was described as episodic in only 33.9% of cases; in the majority of cases it was described as correlated to physical activity, or as occurring spontaneously during the day and/or night. Finally, 7.5% of patients did not report any of these clinical signs. The percentage of patients who reported one symptom only was 38.7%; 33.6% reported two symptoms, 14.2% reported three, and 5.9% of patients four or more symptoms.
The prevalence (%) of basic symptoms in the different patient subgroups is summarized in Table 3 . As can be seen, dyspnoea was the dominant symptom and showed a rising prevalence as lung functions declines. All other symptoms showed the same trend, while the portion of 'asymptomatic' subjects showed an opposite trend, reaching zero in the most severe group. Cough and sputum instead had a nonlinear ('u-shaped') trend, with an increase in the prevalence at the two extremes of FEV 1 values. In particular, subjects with FEV 1 50-60% predicted were symptomatic particularly in terms of dyspnoea and wheezing, but to an extent very similar to that of milder patients.
The findings for some of the basic pharmacoeconomic markers in the different FEV 1 subgroups is presented in Tables 4 and 5 . From Table 4 one can see that hospital admissions are directly in proportion to COPD severity, as defined in functional terms. The same trend was found for the length of hospital stay, recourse to GP and specialist, as well as for the duration of abstention from everyday activities. The increasing trend of these indicators in parallel to COPD severity was also confirmed with regard to the number of exacerbations per patient and number of cycles of oral steroids and antibiotics prescribed at the various levels of severity of subjects.
The subset with FEV 1 50-60% predicted was found to be quite peculiar. In contrast to the occurrence of clinical signs, their pharmacoeconomic indices and the corresponding consumption of healthcare resources were markedly higher when compared with those of milder stages (Duncan test: rate of hospitalization p50.01; length of stay p50.01; medical visits p50.03; rate of exacerbation p50.008; use of oral steroids and antibiotics, both p50.01), thus resembling more closely those of severe COPD (as defined in clinical and functional terms).
Furthermore, as FEV 1 declined, there was a parallel decline in the proportion of asymptomatic and low-symptom patients, while there was a progressive increase in patients reporting a larger number of symptoms (Table 6 ). The subset of subjects with FEV 1 50-60% predicted was found to be in a critical position, probably 0.3 (0.7) 2.0 (7.4) 2.7 (7.9) 1.1 (1.3) 0.7 (0.7) 430 50 0.3 (0.6) 2.6 (6.7) 3.4 (7.4) 1.4 (1.5) 0.7 (0.6) 530 0.5 (0.5) 3.9 (8.4) 4.6 (11.0) 0.9 (1.1) 0.9 (0.9) 1.3 (0.9) 1.4 (0.9) 1.7 (0.8)
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warranting a more aggressive pharmacological treatment of the disease with respect to what would be generally hypothesized for their mildto-moderate COPD.
The treatment approach recorded on the occasion of the first visit in the different subgroups is presented in Table 7 . First, it should be noted that, independently of the COPD severity, the proportion of patients who received no treatment ranged from 9% to 14%. This means that approximately one in eight patients with COPD, including severe, still do not receive any specific treatment.
Respiratory drugs are still not prescribed in 35-45% of subjects with FEV 1 550% predicted, being almost always prescribed only, in fact, in the severe and very severe stages of COPD. The treatment approach, on the basis of GOLD guideline recommendations, was in fact found to be appropriate in less than 40% of patients in the milder stages of COPD but in more than 90% of patients in the severer stages of disease.
Concerning the subgroup with FEV 1 50-60% predicted, the level of treatment appropriateness, previously 36.4% of patients, rose immediately to 53.0% on the heels of the recent ministerial indication. This suggests that, before this provision, these patients were already regularly (and to their benefit) being prescribed treatment options that were previously indicated only for more advanced stages of the disease.
Long-acting bronchodilator drugs never registered a frequency of use above 30%, although there was a rising trend based on clinical severity of the disease. Conversely, in the milder phases of disease, combinations of ICS/LABA showed a frequency of use more or less independent of the degree of original functional deficit, while this use resulted in proportion to the functional deficit in cases of greater clinical severity. Also, the treatment approach concerning subjects with FEV 1 50-60% predicted was indicative. The spontaneous prescription behaviour at local 'grassroots' level resulted in fact more similar to what is recommended in cases of greater clinical severity of COPD, and this was already the case prior to the recent decree extending their use.
Discussion
When facing a complex disease like COPD, which is characterized by a slow progressive decline of lung function over a period of several decades [Fletcher and Peto, 1977] , and for which the possibility of affecting positively the determinants of disease progression has not yet been well defined, it is very difficult to discriminate what pharmaceutical interventions should be considered appropriate or not in 'real life', and when treating patients would start to be effective from a future perspective.
The scientific evidence leads to conflicting results, even if, general speaking, the use of only bronchodilators (both short and/or longacting) have generally always been suggested in 'mild' and 'moderate' COPD (up to FEV 1 50% predicted), thus limiting the use of ICS/LABA combinations exclusively in more severe patients (with FEV 1 550% predicted), or in cases of frequent exacerbators [Global Initiative for Chronic Obstructive Lung Disease, 2006]. Irrespective of whether one agrees or not with such a schematic and deterministic decisional attitude, rather than an approach based on decisions targeted to the phenotype of the individual COPD patient, the criteria of appropriateness referred to for the treatment options are still based on this decisional platform.
In recent years numerous studies have been carried out comparing the medium long-term efficacy of the different treatment options available.
Essentially, attention has focused on the evaluation of the effects of long-acting bronchodilators (LABA and anticholinergics) and of ICS, the latter having given rise to heated discussion in the scientific world in terms of their efficacy in the course of COPD Suissa et al. 2008; Wedzicha et al. 2008; Kardos et al. 2007; Wouters et al. 2005; Calverly et al. 2003; Dal Negro et al. 2003; Szafranski et al. 2003 ].
Evidence in favour of and against has been published, but the general consensus is that the combined administration of ICS and LABA should be indicated as starting from stage III COPD. The present study has shown that the clinical pattern of patients belonging to this particular subset of COPD severity is atypical indeed. In fact, these patients claim respiratory symptoms to a similar extent to that of milder patients, but conversely, their consumption of healthcare resources is much higher and much similar to that of more severe patients. Also the hospitalization and exacerbation rates seem to confirm the dichotomy existing between their claim of clinical signs and pharmaco-economic outcomes.
This evidence seems to suggest that this subgroup of subjects is also in a peculiar condition in terms of a therapeutic strategic decision; they are, in fact, potentially underestimable in clinical terms (and they are presumably difficult to intercept in real life because they are largely unaware of the relevance of their pathological condition), but they already prove a substantial socioeconomic impact, thus leading to the suggestion that an earlier and regular treatment would likely be much more effective in terms of disease progression for these subjects.
The extension of ICS/LABA combination for treatment of this particular level of COPD severity seems worthy of great attention from a perspective point of view. In fact, for the first time a therapeutic decision was in favour of the earlier action against the underlying pathogenetic mechanisms of the disease, which could result in a strategic value in affecting the natural history of the disease itself. On the other hand, the ability to affect disease progression and lung function decline by means of our therapeutic interventions can be effectively expected only before the 'no return' stages of COPD, in other words only when lung function is not yet heavily compromised and lung structures can still be correspondingly stimulated.
Moreover, recent contributions from post-hoc analyses carried out on the overall population of the TORCH study emphasized that lung function decline can also be significantly, even if slightly, affected by ICS/LABA versus placebo [Celli et al. 2008 ]. The peculiar dual profile (i.e. clinical and pharmacoeconomic) shown in the present paper by patients with FEV 1 50-60% predicted contributes to further support this hypothesis and stimulates studies oriented to the assessment of long-term effects and outcomes of early treatment of COPD patients, such as the less severe ones.
Furthermore, to emphasize that the proportion of COPD patients who stand to benefit by the recent extension of ICS/LABA use is not at all negligible in quantitative terms, they in fact represent 20% of subjects with FEV 1 580% predicted, thus suggesting that the global impact of this recent extension would correspond to substantial effects both in clinical terms for the patients, and in health costs for the community and the National Health Service. This hypothesis should be further investigated by means of longterm studies, strategically oriented to the monitoring of COPD impact, particularly when the therapeutic action started when patients' lung function was less compromised.
Finally, the question of the overall undertreatment of COPD patients still remains open. Once again, data from the present study show that the therapeutic treatment of COPD is still far from being considered acceptable in terms of pharmacological appropriateness, particularly in less severe patients, where, given the progressive nature of the disease, the therapeutic attention should be concentrated.
Conclusions
The analysis of the clinical profile of COPD patients with FEV 1 50-60% predicted, to whom the use of ICS/LABA has recently been extended, seems to confirm that these patients are particularly suitable for a long-term assessment of the potential impact of this novel strategic option. They are coupling in fact the characteristics of milder subjects in terms of respiratory symptoms but are characterized by therapeutic needs corresponding to those of more severe patients: they likely represents a peculiar phase in the disease progression of COPD which could be affected much more effectively by an earlier start and a long-duration of the therapeutic strategy. Finally, the overall approach to COPD treatment still ignores intrinsic COPD severity and is insufficient when compared with international guideline recommendations.
